Novartis (NVS) is on the hunt for next-generation obesity drug candidates, despite its main focus remaining on therapeutic areas where it has an established presence, The Wall Street Journal reported Tuesday, citing an interview with Chief Executive Vasant Narasimhan.
"The bar is very high, we need to find something that's truly differentiated, that brings something new," Narasimhan told the Journal.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Price: 105.49, Change: +0.01, Percent Change: +0.01
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.